Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
grade D 63.79 0.03% 0.02
GILD closed up 0.03 percent on Monday, March 25, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical GILD trend table...

Date Alert Name Type % Chg
Mar 25 Lizard Bullish Bullish Day Trade Setup 0.00%
Mar 25 Bollinger Band Squeeze Range Contraction 0.00%
Mar 25 Doji - Bullish? Reversal 0.00%
Mar 22 Fell Below 20 DMA Bearish 0.03%
Mar 22 180 Bearish Setup Bearish Swing Setup 0.03%
Mar 22 Bollinger Band Squeeze Range Contraction 0.03%
Mar 21 Crossed Above 20 DMA Bullish -1.74%
Mar 21 Pocket Pivot Bullish Swing Setup -1.74%
Mar 21 Bollinger Band Squeeze Range Contraction -1.74%
Mar 20 Fell Below 20 DMA Bearish -1.30%

Older signals for GILD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Organic Chemistry Cystic Fibrosis Cardiovascular Diseases HIV Pulmonary Arterial Hypertension Hepatotoxins Respiratory Diseases Prodrugs AIDS Cytomegalovirus Retinitis Fungal Infections
Is GILD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 79.61
52 Week Low 60.32
Average Volume 7,281,141
200-Day Moving Average 70.8225
50-Day Moving Average 66.5664
20-Day Moving Average 64.671
10-Day Moving Average 64.867
Average True Range 1.3332
ADX 17.47
+DI 16.2554
-DI 28.5598
Chandelier Exit (Long, 3 ATRs ) 62.4704
Chandelier Exit (Short, 3 ATRs ) 65.9546
Upper Bollinger Band 66.5841
Lower Bollinger Band 62.7579
Percent B (%b) 0.27
BandWidth 5.916408
MACD Line -0.531
MACD Signal Line -0.56
MACD Histogram 0.029
Fundamentals Value
Market Cap 83.31 Billion
Num Shares 1.31 Billion
EPS 9.21
Price-to-Earnings (P/E) Ratio 6.93
Price-to-Sales 3.57
Price-to-Book 4.49
PEG Ratio -1.08
Dividend 2.08
Dividend Yield 3.26%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 65.38
Resistance 3 (R3) 65.27 64.63 65.12
Resistance 2 (R2) 64.63 64.23 64.69 65.03
Resistance 1 (R1) 64.21 63.97 63.89 64.32 64.94
Pivot Point 63.57 63.57 63.41 63.63 63.57
Support 1 (S1) 63.15 63.17 62.83 63.26 62.64
Support 2 (S2) 62.51 62.91 62.57 62.55
Support 3 (S3) 62.09 62.51 62.47
Support 4 (S4) 62.20